IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
Author(s) -
Pavel A. Nikitin,
Jillian DiMuzio,
John P. Dowling,
Nirja Patel,
Jamie L. Bingaman,
Baron C. Heimbach,
Noeleya Henriquez,
Chris Nicolescu,
Antonio Polley,
Eden L. Sikorski,
Raymond J. Howanski,
Mitchell Nath,
Halley Shukla,
Suzanne M. Scheaffer,
James P. Finn,
Lifang Liang,
Thomas Smith,
Nadia Storm,
Lindsay G. A. McKay,
Rebecca I. Johnson,
Lauren E. Malsick,
An. Honko,
Anthony Griffiths,
Michael Diamond,
Purnanand Sarma,
Dennis H. Geising,
Michael J. Morin,
Matthew K. Robinson
Publication year - 2022
Publication title -
science immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.83
H-Index - 51
ISSN - 2470-9468
DOI - 10.1126/sciimmunol.abl9943
Subject(s) - antibody , monoclonal antibody , in vivo , virology , avidity , in vitro , epitope , biology , antibody dependent cell mediated cytotoxicity , neutralizing antibody , immunology , biochemistry , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom